CERO THERAPEUTICS HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 45.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-04-15
- CERO THERAPEUTICS HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for the quarter ending 2025-03-31 was 45.00%.
- CERO THERAPEUTICS HOLDINGS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was 45.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 2 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 5 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 8 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 11 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 45.00% 10-K · filed 2026-04-15 | |||||||
| 2025-09-30 | 45.00% 10-Q · filed 2025-11-19 | |||||||
| 2025-06-30 | 45.00% 10-Q · filed 2025-08-22 | |||||||
| 2025-03-31 | 45.00% 10-Q · filed 2025-05-15 | |||||||
| 2024-12-31 | 45.00% 10-K · filed 2025-04-15 | |||||||
| 2024-09-30 | 45.00% 10-Q/A · filed 2024-11-20 | |||||||
| 2024-06-30 | 45.00% 10-Q · filed 2024-08-14 | |||||||
| 2024-03-31 | 45.00% 10-Q · filed 2024-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |